source
- BioVie’s Parkinson drug data prompts 50% stock drop as company shifts to composite endpointBioVie announced phase 2 results for its experimental Parkinson’s therapy bezisterim, saying the data suggest a meaningful advance in treating the disease. Investors reacted sharply, wiping out ro…
- AI’s role in medicine isn’t monolithic, says industry leader, urging nuanced adoptionPriya Abani, CEO of health‑tech firm AliveCor, argues that asking whether AI is good for medicine is a question with an obvious answer: it is. She says the debate has become redundant and that the…